Furthermore, numerous properly established adverse prognostic markers, including U-CLL, ATM aberrations or NOTCH1/BIRC3 mutations, lost their negative effect in individuals treated with VO. The one variable that remained predictive of a shorter progression-no cost survival Within this cohort of sufferers was TP53 aberrations.112 Ultimately, the alt